Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to 2-[(4-piperidyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivatives, to their preparation and to pharmaceutical compositions containing them.
• the present invention provides a compound of formula (I) as shown in scheme 1 on the following page, in which R is,
• a linear or branched (C 1 -C 6 ) alkyl group for example a methyl group; an allyl group; a cycloalkylmethyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms, for example a cyclohexyl moiety; a phenylmethyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms, for example chlorine or fluorine atoms, and triflluoromethyl, nitro, amino, dimethylamino, cyano, aminocarbonyl, linear or branched (C 1 -C 3 ) alkyl, linear or branched (C 1 -C 3 ) alkoxy, for example methoxy or ethoxy, and linear or branched (C 1 -C 3 ) alkylthio, for example methylthio, groups; a 2-phenylethyl group; a 3-phenylpropyl group;
• a linear or branched (C 2 -C 6 ) alkanoyl group for example an acetyl group; a cycloalkylcarbonyl group in which the cycloalkyl moiety has from 3 to 6 carbon atoms, for example a cyclohexyl moity; a trifluoroacetyl group; a phenylcarbonyl group unsubstituted or substituted with one to three substituents chosen from halogen atoms, for example chlorine or fluorine atoms, and trifluoromethyl, nitro, linear or branched (C 1 -C 3 ) alkyl, for example methyl, linear or branched (C 1 -C 3 ) alkoxy, for example methoxy or ethoxy, and linear or branched (C 1 -C 3 ) alkylthio, for example methylthio, groups; a 1-oxo-3-phenyl-2-propenyl group; a nap
• the substituents on the phenyl rings may be in the 2,3 or 4 position if there is one substituent, in the 2, 3; 2, 4; 2, 5; 3, 4 or 3, 5 positions if there are two substituents or in the 2, 3,4; 2,3,5; 2,3,6; 2,4,5 or 2,4, 6 positions if there are three substituents.
• Preferred compounds are shown in the following Table. They may be present in the form of the free base or as any other pharmacologically acceptable acid addition salt apart from the ones shown.
• the compounds of formula (I) may be prepared by a process as illustrated in Scheme 1 above.
• the present invention provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a hydrogen atom, i.e. a compound of formula (IX), or a pharmacologically acceptable acid addition salt thereof, which comprises reducing a compound of formula (VI) as shown in Scheme 1 with lithium aluminium hydride or a simple or complex boron hydride, for example diborane or a borane/methyl sulphide complex, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• R is a hydrogen atom, i.e. a compound of formula (IX), or a pharmacologically acceptable acid addition salt thereof, which comprises reducing a compound of formula (VI) as shown in Scheme 1 with lithium aluminium hydride or a simple or complex boron hydride, for example diborane or a borane/methyl sulphide complex, and if desired, forming
• the present invention also provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a group as defined in (b) above, which comprises reducing a compound of formula (VII) as shown in Scheme 1 in which R is as defined above, with lithium aluminium hydride or a simple or complex boron hydride, for example diborane or a borane/methyl sulphide complex, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• the present invention additionally provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a group as defined in (c) above, i.e. a compound of formula (X) as shown in Scheme 1 in which R'CO is a R as defined above, or a pharmacologically acceptable acid addition salt thereof, which comprises reacting 1,2,3,4-tetrahydroisoquinoline of formula (II) as shown in Scheme 1 with a tosylate of formula (XI) as shown in Scheme 1 in which Tos is a tosylate group and R'CO is as defined above, in the absence or presence of an inert solvent, for example dimethylformamide or xylene, at a temperature of 20 to 150° C., optionally in the presence of an organic or inorganic base, for example a tertiary amine or an alkali metal carbonate or hydrogencarbonate.
• R is a group as defined in (c) above, i.e
• the present invention further provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a group as defined in (c) above, i.e. a compound of formula (x) in which R'CO is a group R as defined above, or a pharmacologically acceptable acid addition salt thereof, which comprises reacting a compound of formula (I), in which R is hydrogen, i.e.
• a compound of formula (IV) with a compound of formula RY in which R is as defined above and Y is a labile group, for example a halogen atom such as a chlorine atom, a 1-imidazolyl group, a C 1 -C 6 alkoxy group or an acyloxy group of formula R'CO 2 wherein R'CO is the group R as defined above, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• R is as defined above and Y is a labile group, for example a halogen atom such as a chlorine atom, a 1-imidazolyl group, a C 1 -C 6 alkoxy group or an acyloxy group of formula R'CO 2 wherein R'CO is the group R as defined above, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• the reaction may be carried out in the presence of an organic base, for example triethylamine, in a solvent, for example dichloromethane or ethyl acetate.
• a solvent for example dichloromethane or ethyl acetate.
• Y is a 1-imidazoyl group
• the compound of formula RY may be prepared in situ from the corresponding acid of formula ROH and N,N'-carbonyldiimidazole.
• the reaction may, for example, be carried out in a solvent, such as tetrahydrofuran.
• the compound of formula (IX) may, for example, be reacted with a trialkylaluminium, for example trimethylaluminium, and the complex thus formed reacted with the compound of formula RY, for example at a temperature of from 50° to 110° C. in an inert aromatic solvent such as toluene.
• a suitable reaction temperature is 0° to 60° C.
• the present invention also provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a group as defined in (b) above, which comprises reducing a compound of formula (I) in which R is a group as defined in (c) above, i.e. a compound of formula (X) with a simple or complex boron hydride, for example diborane or a borane/methyl sulphide complex, or with lithium aluminium hydride or aluminium hydride, in an ethereal solvent, for example diethyl ether, tetrahydrofuran or dioxane, at a temperature of from 20° to 100° C.
• a simple or complex boron hydride for example diborane or a borane/methyl sulphide complex
• lithium aluminium hydride or aluminium hydride in an ethereal solvent, for example diethyl ether, tetrahydrofuran or di
• the present invention additionally provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a group as defined in (b) above, which comprises alkylating a compound of formula (I) in which R is a hydrogen atom, i.e. a compound of formula (IX), with a compound of formula RX in which R is a group as defined in (b) above and X is a labile group, for example a halide atom, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• the present invention further provides a process for preparing a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in which R is a hydrogen atom, i.e. a compound of formula (IX), or a pharmacologically acceptable acid addition salt thereof, which comprises hydrogenolysis of a compound of formula (I) in which R is a phenylmethyl group in the presence of palladium, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• R is a hydrogen atom, i.e. a compound of formula (IX), or a pharmacologically acceptable acid addition salt thereof, which comprises hydrogenolysis of a compound of formula (I) in which R is a phenylmethyl group in the presence of palladium, and if desired, forming a pharmacologically acceptable acid addition salt of the compound thus obtained.
• the compound of formula (VII) may, for example, be prepared by alkylating a compound of formula (IV) as shown in Scheme 1 in which R is a group as defined in (b) above with a compound of formula RX in which R is as defined above and X is a labile group, for example a halide atom such as a bromine atom.
• the compound of formula (VII) may also, for example, be prepared by the catalytic hydrogenation of a compound of formula (V) as shown in Scheme 1 in which R is a group as defined in (b) and X is a labile group, for example a halide atom such as a bromine atom.
• the compound of formula (VII) may additionally, for example, be prepared by reacting 1,2,3,4-tetrahydroisoquinoline of formula (II) with an isonipecotate of formula (VIII) as shown in Scheme 1 in which R is as defined in (b), in the presence of trimethylaluminium.
• the compound of formula (V) may, for example, be prepared by the alkylation of an amide of formula (IV) as shown in Scheme 1 with a compound of formula RX in which R is a group as defined in (b) and X is as defined above in relation to the compound of formula (V).
• the compound of formula (VI) may be prepared, for example, by hydrogenolysis, in the presence of palladium, of a compound of formula (VII) in which R is a phenylmethyl group. It may also, for example, be prepared by catalytic hydrogenation of a compound of formula (IV), for example under the conditions described in US-A-4,243,666.
• the compound of formula (IV) may, for example, be prepared by the reaction of 1,2,3,4-tetrahydroisoquinoline with an imidazolide of formula (III) as shown in Scheme 1, prepared in situ from isonicotinic acid and N,N'-carbonyldiimidazole.
• the tosylate of formula (XI) may, for example, be prepared according to the method illustrated in Scheme 2 above.
• a 4-piperidinecarboxylate of formula (XII) (in which Alk is a lower alkyl group) is reduced, for example by means of lithium aluminium hydride, to obtain 4-piperidinemethanol of formula (XIII), which is reacted with an acid chloride of formula R'COCl, in which R'CO is a group as defined in (b), in an inert solvent, such as a chlorinated solvent, at a temperature of 20° to 80° C.
• An ester amide of formula (XIV) is thereby obtained, which is saponified, for example by means of sodium hydroxide or potassium hydroxide, in a lower aliphatic alcohol solvent, preferably ethanol, to obtain an alcohol of formula (XV), which is then reacted with tosyl chloride in a basic medium such as pyridine to form the tosylate of formula (XI).
• a lower aliphatic alcohol solvent preferably ethanol
• a compound of formula (I) in which R is a phenylmethyl group bearing an aminocarbonyl group may be obtained from a compound of formula (I) in which R is a phenylmethyl group bearing a cyano group, by reacting the latter with gaseous hydrochloride acid in the presence of formic acid.
• a compound of formula (I) in which R is a phenylmethyl group bearing an amino group may be obtained from a compound of formula (I) in which R is a phenylmethyl bearing a nitro group, by reduction of the latter by means of diborane or the diborane/methyl sulphide complex, in an ethereal solvent such as tetrahydrofuran.
• a compound of formula (I) in which R is a phenylmethyl group bearing a dimethylamino group may be obtained from a compound of formula (I) in which R is a phenylmethyl group bearing an amino group, by reductive amination of the latter, that is to say by reaction with formaldehyde in the presence of an acid such as sulphuric acid, in an ethereal solvent such as tetrahydrofuran, followed by reduction of the adduct thereby obtained by means of sodium borohydride.
• a catalytic hydrogenation of 35 g (127.3 mmol) of 2-[(4-pyridyl)carbonyl]-1,2,3,4-tetrahydroisoquinoline hydrochloride in 600 ml of methanol is performed in the presence of 1.2 g of platinum oxide, for 17 h, under a hydrogen pressure of 0.38 MPa.
• the catalyst is then filtered off, the methanol evaporated off, the residue taken up with ether and the insoluble material filtered off.
• 33.7 g of hydrochloride are obtained, from which the base is liberated by introducing it into a mixture of water and dichloromethane, adding potassium carbonate portionwise to pH>10.
• the organic phase is separated off and dried over sodium sulphate and the solvent evaporated off.
• the residue is recrystallized in ether, filtered off, washed with pentane and dried. 17.2 g of base are obtained. Melting point: 200°-205° C. (decomposition).
• the mixture is heated under reflux for 2 h, approximately 250 ml of solvent being removed by means of a Dean and Stark apparatus.
• the mixture is cooled in an ice bath and hydrolysed by slowly adding 250 ml of water, and the insoluble material is filtered off, it being rinsed with ethyl acetate.
• the filtrate is washed three times with water, the organic phase dried over sodium sulphate, the solvent evaporated off and the residue recrystallized in cyclohexane. 116.6 g of product are obtained. Melting point: 98°-100° C.
• the organic phase is separated off, washed twice with water and dried, and the solvent evaporated off.
• the residue is taken up with 200 ml of ethanol, a stream of gaseous hydrochloric acid is passed through it and the mixture is heated under reflux for 6 h.
• the solvent is evaporated off, the residue taken up with ether and water, concentrated ammonia solution added, the organic phase separated off, washed with water and dried and the solvent evaporated off. 6.9 g of oily product are obtained, and this is dissolved in isopropyl alcohol, a stream of gaseous hydrochloric acid is passed through it and the salt is recrystallized in ethanol. 7.8 g of dihydrochloride are obtained. Melting point: 260°-265° C.
• the mixture is poured into ice-cold water and extracted with dichloromethane, the organic phase separated off, washed with ammonia solution and then with water and dried over magnesium sulphate and the solvent evaporated off under reduced pressure.
• the mixture is stirred for 20 h at room temperature and then filtered, and the filtrate is washed with water, dried and evaporated under reduced pressure.
• the residual oil is purified by chromatography on a silica column, 7 g of an oil are obtained and this is dissolved in 20 ml of methanol, this solution is added to 2.02 g of fumaric acid dissolved in 20 ml of methanol, the mixture is evaporated, the residue is crystallized in ether and the solid is then recrystallized in isopropyl alcohol. 7.4 g of fumarate are finally isolated. Melting point: 162°-164° C.
• the residue is purified by chromatography on a silica column, eluting with a 95:5 dichloromethane/methanol mixture. A red oil is recovered, which is dissolved in ether. An insoluble material forms which is removed by filtration, and the filtrate is concentrated.
• the difumarate is prepared by dissolving 2.1 g of fumaric acid in 50 ml of methanol and adding 3.34 g of base dissolved in 30 ml of ethyl acetate thereto. The salt crystallizes, and it is washed with ethyl acetate and then with ether and dried under vacuum. Melting point: 203°-205° C.
• the mixture is stirred for 15 min, heated under reflux for 4 h and then left to stand at room temperature.
• the complex is destroyed by adding 10 ml of methanol followed by 5 ml of concentrated hydrochloric acid, and the mixture is heated for a further 6 h under reflux.
• the solvents are evaporated off under reduced pressure, the residue is taken up with water and its pH is adjusted to 10 by means of concentrated ammonia solution.
• the mixture is extracted by means of ethyl acetate, and the organic phase washed with saturated sodium chloride solution to neutrality and dried over sodium sulphate.
• the solvent is evaporated off under reduced pressure, and 4.2 g of an orange oil which partially crystallizes are obtained. It is dissolved in 100 ml of ethanol, the solution is filtered and a solution of 1.85 g (16 mmol) of fumaric acid in 100 ml of ethanol is added to the filtrate.
• the mixture is stirred under a hydrogen pressure 0.35 MPa until the absorption is complete, equivalent to approximately 18 h.
• the catalyst is filtered off and washed with ethanol, and the filtrate is evaporated, neutralized with ammonia solution and extracted with dichloromethane.
• the residue is purified by chromatography on a silica column, eluting first with a 97:3 dichloromethane/methanol mixture, and then a 96:4 dichloromethane/methanol mixture. 6.2 g of a yellow oil are obtained.
• a stream of gaseous hydrochloric acid is bubbled through a mixture of 2.3 g (66 mmol) of 2-[ ⁇ 1-[(3-cyanophenyl)methyl]-4-piperidyl ⁇ methyl]-1,2,3,4-tetrahydroisoquinoline (free base) and 30 ml of formic acid, the disappearance of the starting compound being followed by thin layer chromatography.
• the difumarate is prepared by treating 2.5 g (6.84 mmol) of base with 1.59 g (13.7 mmol) of fumaric acid, in methanol. Melting point: 216°-217° C.
• the catalyst is filtered off, the filtrate concentrated under reduced pressure and the residue purified by chromatography on a silica column, eluting with a 90:10 dichloromethane/methanol mixture. After recrystallization in pentane, 1.9 g of purified base are collected.
• the mixture is heated to approximately 50° C. and 3.02 g (20 mmol) of ethyl 2-pyridinecarboxylate, dissolved in 15 ml of toluene, are added, approximately 10 ml of solvents is removed by means of a Dean and Stark apparatus and the mixture is heated under reflux for 3 h.
• the mixture is stirred for a further 1 h, poured into water and extracted with dichloromethane; the organic phase is washed twice with water, dried over magnesium sulphate and filtered, and the solvent is evaporated off under reduced pressure.
• the residue is purified by chromatography on a silica column, eluting with a 98:2 dichloromethane/ methanol mixture. 3 g (8.8 mmol) of base are obtained, this is dissolved in a mixture of dichloromethane and ethanol and a solution of 1 g (8.8 mmol) of fumaric acid in 100 ml of ethanol is added. The solvents are evaporated off and the residue is recrystallized in ethanol. 3.3 g of fumarate are finally isolated. Melting point: 174°-177° C.
• the mixture is filtered, the filtrate washed with 10% strength aqueous sodium hydroxide solution and then with water, dried over magnesium sulphate and filtered, and the solvent evaporated off under reduced pressure.
• oliy residue which crystallizes, are obtained.
• the hydrochloride of this is prepared by adding 0.1 N hydrochloric acid in isopropyl alcohol, and is recrystallized in ethanol. Melting point: 195°-196° C.
• a solution of 12.76 g (0.23 mol) of potassium hydroxide in 75 ml of ethanol and 75 ml of water is added to a solution of 80 g (0.23 mol) of [1-(3-methylbenzoyl)-4-piperidyl]methyl 3-methylbenzoate in 400 ml of ethanol.
• the mixture is stirred at 20° C. for 3 h, the solvent evaporated off under reduced pressure and the aqueous phase extracted with ethyl acetate.
• the organic phase is washed with water and then with saturated aqueous sodium chloride solution, and dried over magnesium sulphate.
• the solvent is evaporated off under reduced pressure and 53 g of alcohol are obtained, this being used without further treatment in the following stage.
• the compounds of the invention were subjected to a series of pharmacological tests which demonstrated their value as substances having therapeutic activity.
• the compounds displace the binding of a labelled specific ligand, [ 3 H]-8-hydroxy-2-di-n-propylaminotetralin (hereinafter designated "[ 3 H]-8-OH-DPAT” and described by Gozlan et al., Nature, (1983), 305, 140-142), to the 5-HT 1A receptors.
• a labelled specific ligand [ 3 H]-8-hydroxy-2-di-n-propylaminotetralin
• the animals used are Sprague-Dawley male rats weighing 160 to 200 g. After decapitation, their brain is removed and the hippocampus excised. The tissue is ground in an Ultra-Turrax Polytron apparatus for 30 s at half the maximum speed in 10 volumes of 50 mM Tris buffer whose pH is adjusted to 7.4 with hydrochloric acid (equivalent to 100 mg of fresh tissue per ml). The homogenized tissues are washed three times at 4° C. by centrifuging them on each occasion for 10 min at 48,000 ⁇ g and resuspending the pellet in cooled fresh buffer. Finally, the last pellet is suspended in the buffer to produce a concentration of 100 mg of original tissue per ml of 50 mM buffer. The suspension is then left to incubate at 37° C. for 10 min.
• the binding with [ 3 H]-8-OH-DPAT is determined by incubating 100 ⁇ l of membrane suspension in a final volume of 1 ml of buffer containing 10 ⁇ M pargyline and 3 ⁇ M paroxetine.
• the IC 50 values lie between 0.001 and 0.3 ⁇ M.
• the central activity of the compounds of the invention was assessed by their effects on the "PGO (pontogeniculooccipital) spikes" induced by reserpine (PGO-R test) in cats, according to the method described by H. Depoortere, Sleep 1976, 3rd Europ. Congr. Sleep Res., adjoin 1976, 358-361 (Karger, Basel 1977).
• test compounds Cumulative doses of test compounds are administered (from 0.001 to 3 mg/kg intravenously) at 30-min. time invervals, 4 h after the intraperitoneal injection of a dose of 0.75 mg/kg of reserpine, to curarized cats under artificial ventilation.
• the electroencephalographic and phasic (PGO-R spike) activities are obtained using cortical and deep (lateral geniculate) electrodes.
• the percentage decrease in the number of PGO spikes, and then the AD 50 the active dose which decreases this number of spikes by 50%, are determined.
• the intravenous ED 50 values lie between 0.001 and 1 mg/kg.
• the results of the tests show that the compounds of formula (I) possess, in vitro, a high affinity and a selectivity for 5-HT 1A type serotoninergic receptors. In vivo, they show an agonist, partial agonist or antagonist activity with respect to these receptors.
• the compounds of the invention may hence be used for the treatment of diseases and conditions directly or indirectly involving the 5-HT 1A type serotoninergic receptors, in particular for the treatment of depressive states, anxiety states and sleep disorders, and for the regulation of food intake, and also for the treatment of vascular, cerebrovascular or cardiovascular conditions such as migraine and hypertension.
• the present invention provides a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, for use in a method of treatment of the human or animal body by therapy, especially for use in a method of treatment of a depressive state, an anxiety state, a sleep disorder, or a vascular, cerebrovascular or cardiovascular condition or for use in the regulation of food intake.
• the present invention additionally provides the use of a compound of formula (I), or a pharmacologically acceptable acid addition salt thereof, in the manufacture of a medicament for the treatment of a depressive state, an anxiety state, a sleep disorder, or a vascular, cerebrovascular or cardiovascular condition or for use in the regulation of food intake.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Anesthesiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (8)

Related Child Applications (1)

Publications (1)

Family

ID=27446582

Family Applications (2)

Family Applications After (1)

Country Status (10)

Cited By (8)

Families Citing this family (9)

Citations (4)

Family Cites Families (3)

• 1988
  • 1988-08-03 EP EP88402022A patent/EP0306375A1/fr not_active Withdrawn
  • 1988-08-04 IL IL87339A patent/IL87339A0/xx unknown
  • 1988-08-05 AU AU20475/88A patent/AU598149B2/en not_active Ceased
  • 1988-08-05 DK DK437588A patent/DK437588A/da not_active Application Discontinuation
  • 1988-08-05 NZ NZ225708A patent/NZ225708A/en unknown
  • 1988-08-05 JP JP63197010A patent/JPH01100167A/ja active Pending
  • 1988-08-05 FI FI883667A patent/FI883667A/fi not_active Application Discontinuation
  • 1988-08-05 NO NO88883485A patent/NO883485L/no unknown
  • 1988-08-05 KR KR1019880010015A patent/KR890003733A/ko not_active Application Discontinuation
  • 1988-08-05 US US07/228,748 patent/US4885302A/en not_active Expired - Fee Related
• 1989
  • 1989-08-30 US US07/400,811 patent/US4945096A/en not_active Expired - Fee Related

Patent Citations (4)

Also Published As

Similar Documents

Legal Events